The Strange Business of Making Health Care Look Cheap While It Gets More Expensive

The hidden question behind prescription drug markets

Why does a system built to lower drug costs so often make them harder to understand, harder to predict, and sometimes even harder to afford?

That is the central tension in modern pharmacy economics. On one side, there is a promise of scale, negotiation, and efficiency: large intermediaries can use their power to secure lower prices, manage formularies, and simplify access. On the other side, the same machinery can become so layered that nobody can easily tell who is saving money, who is taking a cut, and whether the patient is actually better off.

The most unsettling part is not simply that costs are high. It is that the system can be designed to look efficient while generating complexity as a profit center. In that world, opacity is not a bug. It is a business model.

---

When the middleman stops being a middleman

A traditional middleman does one thing well: it connects buyer and seller, takes a fee, and ideally makes the transaction smoother. In prescription drug markets, that picture has become distorted. The modern intermediary does not just connect the parties. It helps define the rules of the game, determines which drugs are favored, influences patient access, and often sits at the center of money flows that are nearly impossible for outsiders to trace.

This matters because a market can only reward efficiency if prices are legible. Once the system becomes a maze of rebates, spreads, administrative fees, rebate guarantees, and preferred networks, the real price of a drug is no longer the sticker price, nor the plan price, nor the patient price. It becomes a moving target negotiated across multiple actors with different incentives.

Think of it like a grocery store where the shelf label, the checkout total, and the distributor invoice are all different numbers, and each participant gets paid more if the customer cannot compare them. That is not a market in the usual sense. It is a pricing architecture built around information asymmetry.

The result is a strange form of economic theater. Insurers can report control, intermediaries can report savings, manufacturers can report list price discipline, and patients can still walk away with a painful bill. Everyone can claim victory because the accounting is fragmented enough to support multiple narratives.

A system does not need to be corrupt in the cartoon sense to be broken. It only needs incentives that reward complexity more than clarity.

---

Scale can save money, but it can also hide it

There is a reason these firms grow so large. Scale in health care purchasing can create real leverage. A larger organization can aggregate demand, negotiate better terms, reduce administrative friction, and standardize operations in ways that smaller players cannot. In theory, this should benefit patients and employers.

But scale has a shadow side: the bigger the intermediary, the easier it is to make the entire market depend on it. Once that happens, the organization is no longer just competing on efficiency. It is competing on indispensability.

That creates a dangerous dynamic. If a company controls the pathway between manufacturer, insurer, pharmacy, and patient, it can extract value from each transition point. Even when it claims to be passing savings downstream, it may be preserving a slice upstream. The question is no longer, “Did the company reduce costs?” The real question becomes, “Who gets to define what counts as cost, and who gets to keep the difference?”

A useful mental model here is the difference between transportation and toll roads. A good road gets you from one place to another cheaply and predictably. A toll road may be justified if it is faster or better maintained. But if every road segment, intersection, and lane change comes with a fee that only insiders understand, then the system is no longer optimizing travel. It is monetizing passage.

Prescription drug markets can drift into exactly that pattern. The intermediary begins as a navigator. Over time, it becomes a toll collector. And because health care is not optional, the usual consumer defenses do not work. Patients cannot simply shop elsewhere when they need a medicine now.

---

The real product is not drugs, it is complexity management

The biggest misconception about the modern prescription supply chain is that the product being sold is medicine. In a narrow sense, yes. But in a financial sense, the more important product is complexity management.

Employers and health plans do not just buy access to pharmaceuticals. They buy relief from administrative burden, negotiating power, formulary design, claims adjudication, utilization management, and the appearance of control over a chaotic category. That bundle is valuable. It explains why huge intermediaries can become so powerful even when many observers suspect the system is not working as advertised.

This creates a paradox. The more complicated the underlying market becomes, the more valuable a large intermediary appears. But the more valuable the intermediary becomes, the more it may have an incentive to preserve or deepen complexity. That is the essence of a self-reinforcing loop:

1. Drug pricing becomes opaque.
2. Buyers seek an expert intermediary.
3. The intermediary becomes indispensable.
4. Indispensability allows the intermediary to shape rules and incentives.
5. The rules become harder to audit, not easier.
6. Opaqueness increases again.

That loop is powerful because it masquerades as professionalism. Complex systems often reward those who can speak in jargon, produce dashboards, and promise optimization. Yet dashboards can be decorative. Savings claims can be statistical tricks. A lower average cost can coexist with higher patient out-of-pocket exposure. The system can be “efficient” for the organization while being brutal for the person standing at the pharmacy counter.

This is why a narrow focus on whether the system is saving money misses the deeper issue. The question is not just whether savings exist. The question is whether savings are verifiable, durable, and aligned with the patient experience.

If no ordinary person can explain where the money goes, the system may be less like a market and more like a financial instrument.

---

Why financial results matter more than slogans

There is a temptation to judge large health care firms by their public messaging: lower costs, better coordination, improved outcomes, value based care, integrated care. Those phrases are not necessarily false. But they are incomplete. The clearest signal of what a company actually does is often not what it says in a press release, but what its financial structure rewards.

When a company reports strong results in a sector known for friction and confusion, it is worth asking what kind of friction is being converted into value. Is the firm profiting because it genuinely eliminates waste? Or because it has become exceptionally good at navigating, arbitraging, and packaging a fragmented system?

That distinction matters. A business can create shareholder value by fixing a broken market, but it can also create shareholder value by becoming the best operator inside a broken market. Those are not the same thing.

Here is a simple way to tell the difference:

• Value creation reduces total system cost, improves patient access, and makes outcomes more transparent.
• Value capture shifts money within the system while preserving or increasing complexity.

Both can look like success on a balance sheet. Only one is true reform.

The prescription market is especially vulnerable to value capture because its participants measure success differently. Manufacturers care about list prices and formulary access. Plans care about premium stability. Employers care about total spend. Pharmacies care about reimbursement margins. Patients care about what they pay today, not the average trend line over a year.

A powerful intermediary can play each side against the others. That is not necessarily illegal or even unusual. But it means the system’s apparent efficiency may be partly an artifact of fragmented incentives. What looks like coordination can be a highly sophisticated form of incentive translation, where money is moved through the system in ways that are difficult to see from any single vantage point.

---

The test of a healthy system: can an outsider see the price?

The best way to judge this market is not by asking whether it is complicated. All health care markets are complicated. The real test is simpler: Can a reasonable outsider trace the price from manufacturer to pharmacy to patient without needing a decoder ring?

If the answer is no, then the market has crossed a threshold. It has become too reliant on private knowledge. And private knowledge in health care is not just a competitive advantage. It is a moral issue, because the end user is often ill, stressed, and unable to bargain.

This is why transparency is not a decorative reform. It is the precondition for accountability. Without transparency, savings are claims. With transparency, savings become evidence.

An analogy helps here. Imagine a restaurant where the menu price is one number, the bill is another, and the kitchen tells the waiter how much of the difference to keep. You might still get fed. But you would never call that a clean pricing system. Yet in prescription drug markets, a version of this arrangement has become normal enough that many people barely question it.

The deeper lesson is that complexity can be weaponized in at least three ways:

1. To obscure rents, allowing intermediaries to take hidden margins.
2. To shift blame, so each actor can claim the problem lies elsewhere.
3. To control behavior, by making it hard for patients and employers to compare options.

Once you see those dynamics, the issue is no longer just about one company or one policy. It is about whether modern health care has confused expertise with legitimacy. Expertise is necessary. But when expertise becomes uncheckable, it starts to function like authority without consent.

---

Key Takeaways

• Ask who benefits from complexity. If a pricing structure becomes harder to understand as it grows more “efficient,” inspect whether the complexity itself is being monetized.

• Distinguish savings from transfer. A lower average cost does not automatically mean patients pay less. Look for who captures the spread.

• Demand legibility, not just negotiation. A good system should let patients, employers, and regulators see the path of money without specialized insider knowledge.

• Evaluate intermediaries by alignment, not size. Scale can be useful, but large firms should be judged by whether they reduce total system friction or simply control it.

• Use the outsider test. If a normal person cannot explain how the drug price is formed, the system probably needs reform, not just better messaging.

---

The real reform is not cheaper drugs, it is visible drugs

The most important insight here is that the central problem is not merely price. It is unaccountable pricing. A drug market can be expensive and still be honest. It can also be opaque and technically efficient while producing bad outcomes for the very people it is supposed to serve.

That is why so many debates about health care miss the core issue. They focus on whether a middleman is useful, when the real question is whether the middleman can be audited. They focus on whether scale lowers administrative burden, when the real question is whether that burden is being reduced or simply relocated into a less visible corner of the system.

In the end, prescription drug markets reveal a broader truth about modern institutions: when the path from value creation to value capture becomes too hard to see, trust erodes and power concentrates. The danger is not only that patients pay more. The danger is that we stop noticing how the price is made invisible.

The reform worth wanting is not just lower drug costs. It is a system where the cost can be seen, understood, and challenged. Because once pricing becomes legible, accountability becomes possible. And once accountability becomes possible, the market has a chance to serve people again, not merely process them.